• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Corporate Presentation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Lead Scientific Team
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • CDX-101
    • CDX-301
    • ZanthoSyn®
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

All SEC Filings

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
Date Form Description PDF XBRL Pages
07/23/18 8-K Current report filing
Documents
EX-99.1
6
06/22/18 EFFECT Notice of Effectiveness 1
06/22/18 8-K Current report filing
Documents
EX-99.1
7
06/22/18 424B3 Prospectus filed pursuant to Rule 424(b)(3) 131
06/21/18 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. 2
06/21/18 SC TO-I/A Issuer tender offer statement
Documents
EX-99.(A)(1)(F)
11
06/21/18 S-4/A Registration of securities issued in business combination transactions
Documents
EX-5.1
EX-23.1
EX-99.2
148
06/20/18 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. 4
06/20/18 SC TO-I/A Issuer tender offer statement
Documents
EX-99.(A)(1)(D)
11
06/20/18 S-4/A Registration of securities issued in business combination transactions
Documents
EX-23.1
EX-99.2
145
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
Subscribe to Receive Updates by E-Mail Cardax News Alerts

Recent News

  • Cardax Reports Q3 2020 ResultsNovember 13, 2020
  • Cardax Reports Q2 2020 ResultsAugust 14, 2020

© 2021 Cardax, Inc. | Disclaimer and Terms of Use

  • About Us
    • Corporate Overview
    • Corporate Presentation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Lead Scientific Team
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • CDX-101
    • CDX-301
    • ZanthoSyn®
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Investor Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Investors
  • News
  • Subscribe